NEW YORK (GenomeWeb) – Avoca and Synthetic Genomics today announced a supply agreement to extract and commercialize natural astaxanthin from algae strains developed by SGI.

The agreement also gives Avoca the exclusive rights to sell in North America products based on SGI-produced astaxanthin. Avoca's parent firm, Pharmachem Laboratories, will market and sell the products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.